Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/8/?d=1Neue Studien: Europe PMCdeIntegrating multi-source data and machine learning to Decipher the psoriasis-COPD comorbidity.https://www.psoriasis-news.de/articles.html/1_articles/integrating-multi-source-data-and-machine-learning-to-decipher-the-psoriasis-copd-comorbidity-r473/No abstract supplied.

Weiterlesen

]]>473Sun, 22 Feb 2026 17:52:44 +0000Depressive symptoms and psoriasis: Domain-specific associations in national cohorts.https://www.psoriasis-news.de/articles.html/1_articles/depressive-symptoms-and-psoriasis-domain-specific-associations-in-national-cohorts-r472/BackgroundPsoriasis is frequently accompanied by depression. However, the role of specific symptom domains, including cognitive-affective and somatic symptoms, as well as potential metabolic mediators between psoriasis and depression, remains unclear.

Methods

We analyzed data from the National Health and Nutrition Examination Survey (NHANES, n = 14,964) and the Health and Retirement Study (HRS, n = 4364). Depressive symptoms were classified into cognitive-affective and somatic domains. Cross-sectional associations were evaluated in NHANES, and longitudinal symptom trajectories were identified in HRS using group-based trajectory modeling. Based on genome-wide association study summary statistics, bidirectional and two-step Mendelian randomization (MR) were performed to assess causality and identify plasma metabolite mediators.

Results

In NHANES, total depressive symptoms (OR = 1.03, 95% CI: 1.01-1.06, P = 0.018) and somatic symptoms (OR = 1.08, 95% CI: 1.03-1.12, P = 0.003) showed positive associations with psoriasis, but not cognitive-affective symptoms. In HRS, persistently high trajectories of total (OR = 1.58, 95% CI: 1.08-2.32, P = 0.018) was associated with psoriasis, with no significant association for the cognitive-affective and somatic domains after full adjustment. MR supported a causal relationship of psoriasis on depression and identified sphingomyelin (d17:2/16:0, d18:2/15:0) and urate as mediators, accounting for 10.2% and 6.8% of the total effect, respectively.

Conclusion

Depressive symptoms were linked to psoriasis in both cross-sectional and longitudinal analyses. Lipid and antioxidant-related pathways involving sphingomyelin and urate may mediate the relationship between psoriasis and depression, offering potential targets for intervention.

Weiterlesen

]]>472Sun, 22 Feb 2026 17:52:44 +0000IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?https://www.psoriasis-news.de/articles.html/1_articles/il-23-inhibitors-in-psoriasis-what-have-we-learnt-so-far-r471/Weiterlesen

]]>471Sun, 22 Feb 2026 17:52:44 +0000Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data.https://www.psoriasis-news.de/articles.html/1_articles/pharmacokinetic-pharmacodynamic-modelling-of-risankizumab-using-chronic-plaque-psoriasis-real-world-data-r470/AimRisankizumab is a high-cost biologic treatment for chronic plaque psoriasis, an immune-mediated inflammatory disease presenting with painful red scaly skin lesions. Inter-individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (PK/PD) model to characterise the relationship between risankizumab exposure and treatment response.

Methods

A sequential population PK/PD model was developed using real-world data (UK Biomarkers of Systemic Treatment Outcomes in Psoriasis study) comprising serial PK and Psoriasis Area and Severity Index (PASI) measures. Models were built using R (V4.3.1) and nlmixr2 (V2.1.1.9). One and two-compartment PK models were tested. A maximal effect turnover model was used to describe PASI, with drug effect on lesion development rate (Kin).

Results

The dataset (82 serum risankizumab concentrations; 101 PASI observations) comprised 50 patients with psoriasis (median weight 79.3 kg; age 47 years). PK data were described by a one-compartment model with first-order absorption/elimination. Absorption rate (Ka) was fixed from the literature (0.229). Estimated clearance was 0.34 L/day, and volume of distribution 12.9 L. Baseline PASI at model initiation, drug potency (EC50) and lesion recovery rate (Kout) were estimated at 23.4, 0.11 mg/L and 0.05 day-1, respectively.

Conclusions

Pharmacokinetic parameters were similar to risankizumab clinical trials. Kout estimates aligned with other psoriasis turnover models, highlighting the capture of disease dynamics that may be applied across drugs. This model may inform personalised dosing based on individual patient characteristics, drug exposure and response, to optimise treatment outcomes.

Weiterlesen

]]>470Sun, 22 Feb 2026 17:38:20 +0000Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-beyond-the-skin-systemic-inflammation-as-a-bridge-to-metabolic-and-hepatic-comorbidities-r469/Weiterlesen

]]>469Sun, 22 Feb 2026 17:38:20 +0000Survey on the management and patient satisfaction levels in individuals with psoriasis and/or psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/survey-on-the-management-and-patient-satisfaction-levels-in-individuals-with-psoriasis-andor-psoriatic-arthritis-r468/Weiterlesen

]]>468Sun, 22 Feb 2026 17:38:20 +0000Guselkumab: Pediatric First Approval.https://www.psoriasis-news.de/articles.html/1_articles/guselkumab-pediatric-first-approval-r467/®) is a fully human IgG1λ monoclonal antibody developed by Johnson & Johnson to selectively target the p19 subunit of interleukin (IL)-23, a cytokine that plays a key role in various immune-mediated inflammatory diseases. Guselkumab is approved in multiple countries worldwide, including the USA and those of the EU, for the treatment of adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately-to-severely active ulcerative colitis and Crohn's disease. In September 2025, guselkumab received its first pediatric approvals in the USA for the treatment of pediatric patients 6 years of age and older and weighing ≥ 40 kg who either have moderate-to-severe plaque psoriasis and are candidates for systemic therapy or phototherapy, or who have active psoriatic arthritis. Subsequently, guselkumab was approved in December 2025 in the EU for the treatment of moderate-to-severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. Johnson & Johnson is currently undertaking phase III development of guselkumab in pediatric patients with Crohn's disease and ulcerative colitis in various countries. This article summarizes the milestones in the development of guselkumab leading to these first pediatric approvals for plaque psoriasis and psoriatic arthritis.

Weiterlesen

]]>467Sun, 22 Feb 2026 17:38:20 +0000Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan.https://www.psoriasis-news.de/articles.html/1_articles/persistence-and-long-term-disease-control-of-interleukin-17-inhibitors-and-interleukin-23-inhibitors-in-patients-with-psoriasis-a-nationwide-cohort-study-in-japan-r466/IntroductionInterleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) are advanced therapeutic options for moderate-to-severe psoriasis. In real-world settings, biologic persistence is commonly used as a proxy for effectiveness and safety, and a treatment-free status following biologic discontinuation may provide insights into disease remission. This study aimed to assess persistence and treatment-free status for IL-17i versus IL-23i among biologic-naïve patients with psoriasis in Japan.

Patients and methods

This retrospective cohort study analyzed data from the Japanese Medical Data Vision database from 01 January 2015 to 31 December 2022. Patients diagnosed with psoriasis who initiated IL-17i or IL-23i during this study period were included. Persistence of the index biologic and post-discontinuation treatment-free status were assessed using Kaplan-Meier methodology. Propensity score methods with inverse probability of treatment weighting and matching were employed to control potential confounding between treatment cohorts.

Results

There were 1,751 and 1,721 patients included in the IL-17i cohort and IL-23i cohort, respectively. Persistence rates for IL-17i were 55.7% [95% CI 53.2-58.1%] at the first year and 21.5% [95% CI 18.9-24.2%] at the fourth year, versus 77.7% [95% CI 75.4-79.8%] and 47.8% [95% CI 42.2-53.2%], respectively, for IL-23i. The risk of discontinuation of IL-23i was half that of IL-17i (adjusted hazard ratio [aHR]=0.49 [95% CI 0.44-0.54]). After discontinuation, 19.2% [95% CI 16.1-22.4%] and 31.5% [95% CI 27.8-41.2%] of patients in the IL-17i and IL-23i cohorts, respectively, remained treatment-free for at least 1 year. Patients treated with IL-23i had a lower risk for resuming systemic therapy after biologic discontinuation (aHR=0.57 [95% CI 0.49-0.67]).

Conclusion

IL-23i was associated with longer persistence and a longer post-discontinuation treatment-free period than IL-17i in patients with psoriasis. These findings may provide actionable insights for healthcare providers and patients as they develop treatment strategies. Future research integrating comprehensive clinical data is warranted to evaluate different treatment strategies, thereby informing clinical decision-making.

Weiterlesen

]]>466Sun, 22 Feb 2026 17:38:20 +0000Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study.https://www.psoriasis-news.de/articles.html/1_articles/ixekizumab-for-the-treatment-of-psoriatic-arthritis-an-italian-multicentric-retrospective-observational-study-r465/No abstract supplied.

Weiterlesen

]]>465Sun, 22 Feb 2026 17:38:20 +0000Development and validation of a prediction model for the risk of relapse in psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/development-and-validation-of-a-prediction-model-for-the-risk-of-relapse-in-psoriasis-r464/Background This study collected and analyzed clinical data from patients with psoriasis, developing and validating a risk prediction model for psoriasis relapse. The aim is to improve the efficiency and accuracy of early screening for psoriasis relapse in clinical practice and to provide a reference for implementing preventive measures. Objective To develop and validate a risk prediction model for psoriasis relapse. Methods A convenience sampling method was used to select 504 psoriasis patients admitted to a tertiary hospital in China between January 2022 and December 2024, including 353 cases in the training set and 151 cases in the test set. Independent risk factors for psoriasis relapse were identified through univariate analysis and logistic regression analysis to develop a prediction model. A nomogram and SHAP summary plot were generated for model visualization, and the model’s goodness of fit and discriminative ability were evaluated. Results The one-year relapse rate of psoriasis patients after treatment was 66.67%. Logistic regression analysis identified body mass index (BMI), diabetes, biologic agent use, smoking, upper respiratory tract infection (URTI), and non-standard medication as independent risk factors for psoriasis relapse, which were included in the model. The area under the ROC curve (AUC) values for the training and testing sets were 0.767 [95% CI: 0.715–0.818] and 0.704 [95% CI: 0.620–0.789], respectively. The model demonstrated good discrimination and calibration, and decision curve analysis (DCA) showed significant net benefit in both the training and testing sets. Conclusion The psoriasis relapse risk prediction model developed in this study demonstrated good predictive performance. This model can serve as an effective reference for assessing the risk of psoriasis relapse and provides valuable insights for developing personalized prevention strategies for patients.

Weiterlesen

]]>464Sun, 22 Feb 2026 17:38:20 +0000Nanocarriers for Psoriasis Treatment: Insights from a Clinical Trial Registered on the Global Clinical Trials Registry Platform.https://www.psoriasis-news.de/articles.html/1_articles/nanocarriers-for-psoriasis-treatment-insights-from-a-clinical-trial-registered-on-the-global-clinical-trials-registry-platform-r463/Weiterlesen

]]>463Sun, 22 Feb 2026 17:38:20 +0000Observation on The Formation of Neutrophil Extracellular Traps in Psoriatic Peripheral Bloodhttps://www.psoriasis-news.de/articles.html/1_articles/observation-on-the-formation-of-neutrophil-extracellular-traps-in-psoriatic-peripheral-blood-r462/Objective To explore the clinical application value of Neutrophil extracellular traps (NETs) in evaluating psoriasis. Methods 2ml peripheral blood of 63 patients with psoriasis and 27 healthy controls were collected. Neutrophils were isolated by density gradient method, and the formation of NETs was observed by immunofluorescence staining. We then calculated the proportion and fluorescence intensity of NETs and analyzed their correlation with clinical classification, severity, and serological indicators. Furthermore, the skin lesions of 5 patients with psoriasis were collected, and the NETs were observed by immunofluorescence method. Results The proportion and fluorescence intensity of spontaneous NETs in patients with psoriasis were significantly higher than those in healthy controls and were positively correlated with the PASI scores. The generation of NETs in psoriasis patients with metabolic syndrome (MetS) or high-TNF-α was higher than in psoriasis patients without metabolic abnormalities or normal-TNF-α. NETs were also observed in most psoriatic skin specimens. Conclusions The levels of NETs are correlated with the disease severity of psoriasis and patients with metabolic abnormalities and may be used as a clinical indicator to reflect the inflammatory state of psoriasis and metabolic comorbidity of psoriasis for disease evaluation.

Weiterlesen

]]>462Sun, 22 Feb 2026 17:38:20 +0000Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study.https://www.psoriasis-news.de/articles.html/1_articles/psychological-well-being-of-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-tildrakizumab-28-week-interim-results-from-a-multicenter-observational-study-in-italy-using-the-dass-21-questionnaire-the-blue-study-r461/IntroductionPsoriasis is a chronic inflammatory skin disease associated with significant physical and psychological burden. Tildrakizumab, an interleukin-23 p19 inhibitor, has demonstrated efficacy in treating moderate-to-severe plaque psoriasis both in clinical trials and real-world setting. However, limited data are available on the impact of the effective treatment of psoriasis on the psychological health of patients. The aim of this study was to assess changes in psychological well-being, as well as clinical and quality-of-life outcomes, in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab in routine clinical practice in Italy.

Methods

This was an interim analysis (IA) of a 52-week multicenter, prospective, observational study. Adults with moderate-to-severe plaque psoriasis initiating tildrakizumab were enrolled. Endpoints focused on well-being and psychological health and included changes, from baseline to week 28, in Depression, Anxiety, and Stress Scale-21 (DASS-21) scores, Dermatology Life Quality Index (DLQI), European Social Survey (ESS) items, and World Health Organization-Five Well-Being Index (WHO-5). Effectiveness was also monitored via Psoriasis Area and Severity Index (PASI), and safety via treatment-emergent adverse event reporting.

Results

A total of 115 patients were included (mean age 52.5 years, 60.8% male), 102 receiving ≥ 1 dose of tildrakizumab and completing DASS-21 evaluations at baseline and week 28. At week 28, improvements were observed in DASS-21 subscales [depression (- 2.6, 95% CI - 2.0 to - 1.0), anxiety (- 2.3, 95% CI - 2.0 to - 1.0), and stress (- 3.4, 95% CI - 4.0 to - 2.0)], accompanied by marked PASI reduction (- 13.7, 95% CI - 12.8 to - 10.1). DLQI, ESS, and WHO-5 scores also improved. Adverse events were generally mild or moderate, with no unexpected safety signals.

Conclusion

In this real-world IA, tildrakizumab was observed to improve the psychological well-being of patients, reflected by a reduction in all items of the DASS-21 scale and, in parallel, confirmed its effectiveness in managing physical symptoms of psoriasis, establishing its role in the holistic management of psoriasis.

Weiterlesen

]]>461Sun, 22 Feb 2026 17:38:20 +0000Exploring the risk association between psoriasis and chronic obstructive pulmonary disease, and asthma using the NHIS database.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-risk-association-between-psoriasis-and-chronic-obstructive-pulmonary-disease-and-asthma-using-the-nhis-database-r459/BackgroundAsthma (AS) and chronic obstructive pulmonary disease (COPD) are prevalent chronic airway disorders with shared inflammatory pathways. Considering the systemic inflammatory nature of psoriasis, this study utilized the National Health Interview Survey (NHIS) to investigate its potential association with COPD and AS.

Methods

Data from the 2023 NHIS were analyzed, with participants selected based on specific inclusion criteria. A baseline table was constructed, and multivariate logistic regression models, along with risk stratification analysis, were employed to examine the correlations between psoriasis and COPD and AS. Receiver operating characteristic (ROC) analysis was conducted to assess the predictive value for both conditions.

Results

A total of 27,106 participants were included in the study. Significant differences were observed in the baseline characteristics of psoriasis, age, race, region, gender, education, marital status, employment, income, smoking habits, health status, mental health, disability, heart attack history, BMI, prediabetes, cancer, hypertension, hypercholesterolemia, arthritis, coronary heart disease, stroke, health insurance, anxiety, and depression (P < 0.001). Multivariate logistic regression revealed a strong association between psoriasis and COPD (model 1: OR 2.63, 95% CI: 2.13-3.23, P < 0.001; model 2: OR 2.43, 95% CI: 1.95-2.99, P < 0.001; model 3: OR 1.54, 95% CI: 1.21-1.96, P < 0.001). A similar association was found between psoriasis and AS (model 1: OR 1.68, 95% CI: 1.42-1.97, P < 0.001; model 2: OR 1.74, 95% CI: 1.47-2.05, P < 0.001; model 3: OR 1.32, 95% CI: 1.11-1.56, P < 0.01). The ROC analysis based on model 3 demonstrated substantial predictive power of psoriasis for COPD, with an AUC of 0.881.

Conclusion

Psoriasis was identified to have a strong association with COPD and AS, which provided valuable insights into understanding the pathogenesis of these diseases.

Weiterlesen

]]>459Sun, 22 Feb 2026 17:23:03 +0000Investigating the role of serum human beta defensin-2 in psoriasis and psoriatic arthritis: a case-control study on hBD-2 and CRP, ESR.https://www.psoriasis-news.de/articles.html/1_articles/investigating-the-role-of-serum-human-beta-defensin-2-in-psoriasis-and-psoriatic-arthritis-a-case-control-study-on-hbd-2-and-crp-esr-r458/IntroductionHuman beta-defensin 2 (hBD-2) is an antimicrobial peptide upregulated by IL-17A and TNF-α, important in skin immunity and inflammation. While hBD-2 is elevated in psoriatic skin, its systemic expression and clinical significance remain unclear, particularly in psoriatic arthritis (PsA).

Objectives

To compare serum hBD-2 levels among patients with psoriasis vulgaris, PsA, and healthy controls, and to evaluate its correlation with disease severity and inflammatory markers.

Methods

This case-control study included 66 patients with psoriasis, 30 with PsA, and 67 healthy controls. Serum hBD-2, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI). A p value < 0.05 was considered statistically significant.

Results

Median serum hBD-2 levels were significantly higher in psoriasis and PsA groups compared to controls (p < 0.001), but no significant difference was found between the two patient groups (p: 0.223). In the psoriasis group, hBD-2 showed no significant correlation with PASI (r: 0.218, p: 0.095), CRP (r: 0.158, p: 0.277), or ESR (r: 0.129, p: 0.369). CRP and ESR were significantly higher in the PsA group than in other groups (p < 0.001 and p: 0.002, respectively).

Conclusions

Although serum hBD-2 is elevated in psoriasis and PsA, it does not correlate with clinical or laboratory disease activity in psoriasis. These findings suggest that hBD-2 may reflect local cutaneous immune activation rather than systemic inflammation.

Weiterlesen

]]>458Sun, 22 Feb 2026 17:23:03 +0000Increased risk of inflammatory bowel disease in ankylosing spondylitis compared to psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/increased-risk-of-inflammatory-bowel-disease-in-ankylosing-spondylitis-compared-to-psoriasis-r457/No abstract supplied.

Weiterlesen

]]>457Sun, 22 Feb 2026 17:23:03 +0000Nail Amino Acid and Trace Element Profiles and Their Association with Clinical Severity in Nail Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/nail-amino-acid-and-trace-element-profiles-and-their-association-with-clinical-severity-in-nail-psoriasis-r456/BackgroundNail involvement is common in psoriasis, yet objective and non-invasive biomarkers of nail disease activity are limited. The biochemical composition of the nail plate may reflect local pathophysiological changes and could provide measurable indicators of disease severity.

Objective

To compare the nail biochemical composition between psoriatic patients with and without nail involvement, and to examine its associations with nail severity.

Methods

In this case-control study, nail clippings from adults with psoriasis were analyzed for trace elements (Cr, Cu, Fe, Mn, Mg, Se, Zn) by ICP-OES and for amino acids by LC-MS/MS. Group comparisons and correlation analyses with the Nail Psoriasis Severity Index (NAPSI) were conducted, and multivariable logistic regression identified independent predictors of nail involvement.

Results

Fifty-seven patients were included (30 with nail involvement; 27 without). Compared with patients without nail involvement, those with nail psoriasis showed significantly lower nail levels of several trace elements and amino acids, whereas histidine was higher (all p < 0.05). NAPSI correlated negatively with selenium, zinc, glycine, and proline, and positively with histidine. In multivariable analysis, lower nail selenium and asparagine and higher histidine independently predicted nail involvement.

Conclusion

Psoriatic nail dystrophy is associated with a distinct biochemical profile in the nail plate. Selected trace elements and amino acids correlate with clinical severity and may represent potential biochemical indicators of nail disease activity. Prospective studies are warranted to validate these findings.

Weiterlesen

]]>456Sun, 22 Feb 2026 17:23:03 +0000[Moderate-severe psoriasis and associated comorbidity in patients on biologic therapy: implications for primary care].https://www.psoriasis-news.de/articles.html/1_articles/moderate-severe-psoriasis-and-associated-comorbidity-in-patients-on-biologic-therapy-implications-for-primary-care-r455/ObjectiveTo describe the comorbidity profile in patients with moderate-to-severe psoriasis treated with biologics and their association with clinical phenotype and therapeutic choice.

Material and methods

This was an observational, cross-sectional, single-center study conducted at the Lozano Blesa University Clinical Hospital (Zaragoza, Spain). Consecutive patients with moderate-to-severe psoriasis receiving biologic treatment were included. Data were collected during the Dermatology consultation and reviewed from medical records. The variables analyzed included demographic data, clinical phenotype, previous and current treatments, cardiometabolic comorbidities, neoplasia, infections, and lifestyle habits. Statistical analysis employed means and proportions comparison tests, and logistic regression to explore associations between phenotype, comorbidities, and biologic type.

Results

350 patients were included (median age 54.1years; 57% men; 84% plaque psoriasis). The most prevalent comorbidities were dyslipidemia (55%), hypertension (42%), and obesity (36%). Among patients with liver elastography, 58% met MASLD criteria. Significant associations were observed between clinical phenotype and comorbidities: plaque psoriasis with hypertension and vitaminD deficiency, erythrodermic psoriasis with alcoholism and neoplasia, pustular psoriasis with dyslipidemia and kidney disease, and guttate psoriasis with a lower prevalence of cardiovascular factors. Guselkumab was the most commonly used biologic (15%).

Conclusions

Patients with moderate-to-severe psoriasis have a high burden of comorbidities, with differential profiles according to phenotype. These results reinforce the need for a multidisciplinary approach and the role of primary care in screening and managing comorbidities to improve disease control and overall prognosis.

Weiterlesen

]]>455Sun, 22 Feb 2026 17:23:03 +0000Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.https://www.psoriasis-news.de/articles.html/1_articles/three-year-patient-reported-outcomes-from-bimekizumab-for-plaque-psoriasis-the-be-radiant-randomized-clinical-trial-with-open-label-extension-r454/ImportancePatient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.

Objective

To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.

Design, setting, and participants

The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients).

Interventions

Continuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab/bimekizumab-treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64.

Main outcomes and measures

Patient-reported itching/skin pain/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years).

Results

A total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal P < .001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal P = .01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal P < .001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI = 0 and DLQI 0/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal P < .001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal P < .001). In patients entering the OLE, high P-SIM = 0 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI = 0 and DLQI 0/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab/bimekizumab-treated patients. After switching, secukinumab/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab/bimekizumab (62.2% and 63.8%, respectively).

Conclusions and relevance

In this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab.

Trial registration

ClinicalTrials.gov Identifier: NCT03536884.

Weiterlesen

]]>454Sun, 22 Feb 2026 17:23:03 +0000Guttate Psoriasis Triggered by Streptococcal Pharyngitis in Older Patients: A Case Report.https://www.psoriasis-news.de/articles.html/1_articles/guttate-psoriasis-triggered-by-streptococcal-pharyngitis-in-older-patients-a-case-report-r453/Weiterlesen

]]>453Sun, 22 Feb 2026 17:23:03 +0000Real-World Predictors of Relapse-Free Duration After Narrowband UVB in Pediatric Psoriasis: A Multicenter Study.https://www.psoriasis-news.de/articles.html/1_articles/real-world-predictors-of-relapse-free-duration-after-narrowband-uvb-in-pediatric-psoriasis-a-multicenter-study-r452/BackgroundNarrowband ultraviolet B (NB-UVB) phototherapy is a well-established, safe, and effective treatment for pediatric psoriasis; however, relapse after therapy remains a major challenge. Data regarding prognostic factors influencing remission durability in children are limited.

Objectives

To evaluate treatment response, relapse patterns, and predictors of relapse-free duration in pediatric psoriasis patients treated with NB-UVB phototherapy, with a particular focus on concomitant topical corticosteroid and calcipotriol use, and clinical features such as nail involvement.

Methods

This multicenter retrospective study included 114 pediatric psoriasis patients treated with NB-UVB across six tertiary dermatology centers in Türkiye. Treatment response was defined as ≥ 75% improvement in the Psoriasis Area and Severity Index (PASI75). Relapse was defined as clinically significant recurrence requiring renewed NB-UVB or systemic therapy within 6 months after treatment completion. Multivariable linear regression identified independent predictors of relapse-free duration.

Results

Of 114 patients (mean age 12.2 ± 3.6 years; 52.6% male), 65.8% achieved PASI75 and 42.1% PASI90. Responders received significantly higher cumulative doses and more sessions than nonresponders (p < 0.001). Relapse occurred in 24.0% of responders within 6 months. In multivariate analysis, concomitant topical corticosteroid use independently predicted longer relapse-free duration (β = 0.578, p = 0.001), whereas nail involvement predicted shorter remission (β = -0.520, p = 0.002). Topical calcipotriol and disease subtype were not significant predictors. NB-UVB was well tolerated, with mild erythema and pruritus as the most frequent adverse events (16.7%).

Conclusion

NB-UVB phototherapy provides high efficacy and an acceptable safety profile in pediatric psoriasis. Concomitant topical corticosteroid use may prolong remission, while nail involvement identifies patients at higher relapse risk, supporting closer monitoring and individualized follow-up and maintenance strategies.

Weiterlesen

]]>452Sun, 22 Feb 2026 17:23:03 +0000Macronutrient intakes and associations with psoriasis severity: a cross-sectional analysis of the asking people with psoriasis about lifestyle and eating (APPLE) study.https://www.psoriasis-news.de/articles.html/1_articles/macronutrient-intakes-and-associations-with-psoriasis-severity-a-cross-sectional-analysis-of-the-asking-people-with-psoriasis-about-lifestyle-and-eating-apple-study-r451/No abstract supplied.

Weiterlesen

]]>451Sun, 22 Feb 2026 17:23:03 +0000Sex hormone–psoriasis interactions: from sex-specific clinical features to immunoregulatory mechanismshttps://www.psoriasis-news.de/articles.html/1_articles/sex-hormonepsoriasis-interactions-from-sex-specific-clinical-features-to-immunoregulatory-mechanisms-r450/No abstract supplied.

Weiterlesen

]]>450Sun, 22 Feb 2026 17:23:03 +0000S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditätenhttps://www.psoriasis-news.de/articles.html/1_articles/s3%E2%80%90leitlinie-zur-therapie-der-psoriasis-vulgaris-adaptiert-von-euroguiderm-teil-2-hilfestellungen-f%C3%BCr-besondere-klinische-situationen-und-bei-vorliegen-von-komorbidit%C3%A4ten-r445/No abstract supplied.

Weiterlesen

]]>445Tue, 10 Feb 2026 08:00:25 +0000Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/real-world-efficacy-and-drug-survival-of-adalimumab-in-australian-patients-with-psoriasis-r444/BackgroundAlthough adalimumab has shown strong efficacy and safety in clinical trials, real-world evidence in Australian patients with moderate-to-severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open-label extension.

Methods

Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan-Meier and Cox regression.

Results

A total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.

Conclusions

In Australian real-world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.

Weiterlesen

]]>444Tue, 10 Feb 2026 08:00:25 +0000